PRP vs hyaluronic acid injections for knee arthritis — which one should you actually get?

The honest answer to the question of PRP versus hyaluronic acid for knee arthritis is that the right choice depends on arthritis severity, and the evidence is more nuanced than most clinics will convey.

Platelet-rich plasma (PRP) works by concentrating growth factors from the patient's own blood to stimulate tissue repair and reduce inflammation. The evidence base for PRP has grown substantially, with randomized controlled trial data showing superiority over hyaluronic acid in early-to-moderate osteoarthritis, and effects that may last 6 to 12 months or longer. PRP is best suited to mild-to-moderate knee osteoarthritis, corresponding to Kellgren-Lawrence Grade 1 through 3. Its limitations are practical as much as clinical: preparation protocols vary widely between clinics, insurance coverage is rare, and upfront cost typically runs $500 to $2,000 or more. The overall evidence grade is B — promising, but heterogeneous across studies.

Hyaluronic acid (HA), also called viscosupplementation, lubricates and cushions the joint and may carry mild anti-inflammatory effects. It is FDA-approved and frequently covered by insurance, which makes it accessible where PRP is not. The evidence picture is mixed: some meta-analyses show modest benefit over placebo, while others find minimal clinically meaningful difference. Effect size tends to be better in less severe osteoarthritis. Like PRP, HA carries an evidence grade of B, though its track record is more established even as its effect size remains debated.

Comparing the two directly, PRP generally offers longer pain relief — on the order of 6 to 18 months — compared to 3 to 6 months for HA. Both show meaningful efficacy in early osteoarthritis, and both show limited efficacy in severe disease. PRP has an excellent safety profile but inconsistent standardization; HA has an equally excellent safety profile with more consistent preparation. Insurance coverage favors HA; evidence quality for both sits at grade B, with PRP's body of literature still maturing.

The practical recommendation follows from this: in mild-to-moderate osteoarthritis, current evidence slightly favors PRP for longer-lasting pain relief, but only when administered by a reputable provider using a validated preparation protocol. When cost or insurance coverage is a barrier, HA remains a reasonable, evidence-supported alternative. Neither injection is appropriate as a standalone treatment for severe osteoarthritis (Grade 4), where surgical consultation is the warranted next step.

Formal grading of osteoarthritis severity — ideally confirmed by X-ray or MRI — is the essential first step, since the injection choice hinges directly on disease grade. For Grade 1 through 3 disease, PRP can be expected to produce roughly 40 to 70% pain reduction lasting 6 to 18 months, while HA typically produces 30 to 50% pain reduction lasting 3 to 6 months. Both interventions are most effective when combined with supervised exercise therapy, which enhances and prolongs injection benefits, and with weight optimization where applicable, which reduces joint load and improves outcomes across all treatment modalities.

Several patient-specific factors bear heavily on the final choice: which compartment is affected (medial, lateral, or patellofemoral), what treatments have already been tried, whether the patient is on anticoagulants or has platelet disorders that would affect PRP candidacy, the presence of conditions such as diabetes or autoimmune disease, and the patient's primary functional goals — whether that is pain relief, return to sport, or surgical delay. Biomechanical factors such as valgus or varus alignment and quadriceps strength, a key predictor of osteoarthritis progression and injection response, also influence how well either injection is likely to perform. How long symptoms have been present and whether they are progressing rounds out the clinical picture needed to individualize the recommendation.

Knee osteoarthritis is not simply cartilage wearing down. It represents a cascade of arthrokinematic failures. The normal roll-glide mechanics of the tibiofemoral joint — where the femur rolls posteriorly and glides anteriorly during flexion — become disrupted as cartilage degrades and synovial fluid loses its viscoelastic properties. This produces abnormal joint compression patterns that load already compromised cartilage unevenly, an altered instant center of rotation that shifts mechanical stress to the medial compartment in most cases, progressive destruction of the mechanoreceptors housed in the cartilage and synovium that creates a neuromuscular feedback loop accelerating dysfunction, and quadriceps inhibition via arthrogenic muscle inhibition, where joint effusion neurologically suppresses the VMO and quad complex even before pain becomes severe. This cascade matters for the injection decision because PRP and hyaluronic acid each target a different part of it.

Hyaluronic acid is a naturally occurring glycosaminoglycan that gives healthy synovial fluid its viscosity and elasticity. In arthritic joints, HA concentration drops and molecular weight decreases — the fluid becomes thin and loses its shock-absorbing capacity. HA injections work by restoring the viscoelastic properties of synovial fluid, improving the fluid film lubrication mechanism, reducing friction during the roll-glide arthrokinematic sequence, providing some anti-inflammatory effect on the synovial membrane, and potentially stimulating endogenous HA production, though that last mechanism remains debated. In biomechanical terms, HA functions as a mechanical intervention — it lubricates a joint that has lost its natural lubricant. This makes it most appropriate for mild-to-moderate OA where the joint space is still reasonably preserved and the primary complaint is stiffness and mechanical pain with activity.

The research on HA is genuinely mixed. Some high-quality meta-analyses, including a notable study published in the New England Journal of Medicine, show HA performs only marginally better than placebo injections. The placebo effect in joint injections is substantial — the act of injecting fluid itself carries mechanical benefit — and certain patient subgroups, particularly those with Kellgren-Lawrence Grade 2-3 OA, do show meaningful clinical benefit.

Platelet-rich plasma is a concentration of the patient's own platelets, typically 3 to 5 times baseline concentration, containing growth factors including PDGF, TGF-β, IGF-1, and VEGF. These are not lubricants; they are biological signaling molecules. PRP works by delivering growth factors that may stimulate chondrocyte proliferation and extracellular matrix synthesis, modulating the inflammatory cytokine environment by reducing IL-1β and TNF-α, and potentially stimulating endogenous HA production by synoviocytes. Where HA addresses mechanical symptoms, PRP targets the disease-modifying pathway — attempting to slow or partially reverse the degenerative process rather than manage symptoms alone. This makes it theoretically more appropriate for active individuals with early-to-moderate OA who want to address the underlying biology.

Recent high-quality randomized controlled trials and meta-analyses from 2020 through 2024 consistently show PRP outperforming both HA and saline placebo for pain reduction and functional improvement at 6 to 12 month follow-up. A 2021 meta-analysis in the Orthopaedic Journal of Sports Medicine found PRP superior to HA across multiple outcome measures, particularly in younger, more active patients.

Knee OA also produces predictable kinetic chain consequences that should inform the treatment decision. Proximally, knee OA almost universally creates a Trendelenburg compensation pattern in which the gluteus medius weakens or inhibits, causing ipsilateral pelvic drop during single-leg stance. Hip external rotators tighten as the body attempts to offload the medial compartment, which paradoxically creates a femoral adduction and internal rotation moment that increases medial compartment loading. Distally, reduced knee flexion during gait increases ground reaction force transmission, the subtalar joint compensates with excessive pronation that further increases tibial internal rotation and medial compartment stress, and Achilles and gastrocnemius tightness becomes a secondary driver of altered knee mechanics. If significant compensatory dysfunction is present throughout the kinetic chain, neither injection alone will be sufficient. The biomechanical environment driving cartilage loss must be corrected simultaneously.

Taken together, the evidence supports PRP as the stronger choice for most active patients under 65 with Kellgren-Lawrence Grade 2-3 OA who want a longer-lasting biological effect. Evidence suggests PRP provides meaningful benefit at 12 or more months compared to roughly 6 months for HA, though patients should expect a 2 to 4 week initial flare period after injection. PRP is typically not covered by insurance and costs between $500 and $2,000 per injection. HA is more appropriate for older patients, particularly those 65 and older, with more advanced OA whose primary complaint is mechanical stiffness and friction-type pain, who need faster symptom relief, or for whom cost is a significant constraint given that some insurance coverage is available. For Grade 4, bone-on-bone OA, the evidence for both treatments drops significantly and surgical consultation is appropriate. Neither injection should substitute for optimized conservative management, including exercise therapy, weight management, and bracing.

The injection is only as good as the movement environment created around it. The following protocol addresses the kinetic chain dysfunctions that must be corrected in parallel.

In the first three weeks after injection, the focus is joint preparation. Patellar mobilizations — superior, inferior, medial, and lateral glides held for 30 seconds each direction, performed three times daily with gentle pressure — are critical for restoring tibiofemoral mechanics. Heel slides for range-of-motion restoration are performed as 3 sets of 15 repetitions twice daily, progressing when the patient achieves 0 to 120 degrees of pain-free range using a smooth surface or towel under the heel. Quad sets with biofeedback use an isometric quad contraction with a towel roll under the knee, held for 10 seconds for 15 repetitions three times daily, with attention to VMO activation confirmed by placing fingers medial to the patella. Ankle pumps — 3 sets of 20 hourly — and a standing gastrocnemius stretch held for 30 seconds three times daily address the distal kinetic chain.

From weeks 3 through 8, the emphasis shifts to neuromuscular re-education. Terminal knee extensions with a resistance band anchored anteriorly and looped behind the knee are performed as 3 sets of 15 daily; this targets the VMO in a functional range and is critical for restoring normal patellar tracking. Forward and lateral step-ups begin on a 4-inch step and progress to an 8-inch step, performed as 3 sets of 12 in each direction three times per week with a slow 3-second eccentric lowering phase. Single-leg balance progresses from eyes open on a firm surface for 3 sets of 30 seconds, to eyes closed, then to an unstable surface such as a foam pad, three times per week, restoring the proprioceptive function lost with cartilage degradation. Side-lying clamshells for glute medius activation — 3 sets of 20 daily, progressing to banded clamshells and then lateral band walks — are non-negotiable, as correcting the Trendelenburg pattern directly reduces medial compartment loading.

From weeks 8 through 16, the program advances to functional loading. Goblet squats with 1-inch heel elevation to reduce posterior tibial shear are performed as 3 sets of 12 three times per week, with load progressed when form is consistent through the full available range. Lateral step-downs from an 8-inch step with a slow 4-second lowering phase — 3 sets of 10 three times per week — are performed with the objective of no knee valgus, no Trendelenburg, and no trunk lean. Gait retraining focuses on restoring a heel-to-toe pattern, slightly increasing step width to reduce the adduction moment, and using treadmill walking with mirror feedback for 20 minutes three times per week.

Progression between phases follows objective criteria. The transition from Phase 1 to Phase 2 requires achieving 0 to 120 degrees of range of motion with pain no greater than 3 out of 10, symmetric gait without a visible antalgic pattern, and a quad set that produces visible VMO contraction. The transition from Phase 2 to Phase 3 requires single-leg balance of 30 seconds or more with eyes closed and without compensation, step-up and step-down performance with no knee valgus collapse, and pain no greater than 2 out of 10 with daily activities. Return to full activity requires a single-leg squat to 60 degrees with no valgus and no Trendelenburg, symmetric gait at varied speeds, and pain no greater than 1 out of 10 with the target activity.

The kinetic chain dysfunctions — gluteus medius weakness, altered roll-glide mechanics, proprioceptive deficits, and compensatory gait patterns — must be systematically addressed alongside whichever injection is chosen, or the underlying biomechanical forces will continue degrading the joint regardless of what is injected.

Platelet-rich plasma and hyaluronic acid represent the two most commonly discussed injection options for knee osteoarthritis, and the evidence increasingly favors PRP — though with important caveats that matter clinically.

PRP has shown superior outcomes over hyaluronic acid in multiple systematic reviews and meta-analyses, particularly for mild-to-moderate knee osteoarthritis classified as Kellgren-Lawrence grades 1 through 3. A 2021 meta-analysis published in The American Journal of Sports Medicine demonstrated that PRP produced significantly greater pain reduction and functional improvement at 6 and 12 months compared to hyaluronic acid. The biological rationale is sound: PRP delivers concentrated growth factors — including PDGF, TGF-β, and IGF-1 — that modulate the inflammatory cascade and may support cartilage matrix preservation.

Hyaluronic acid functions as a viscosupplement, temporarily restoring synovial fluid viscosity and providing mechanical cushioning. It is well-tolerated, has decades of clinical use, and works reasonably well for short-term symptom relief over 3 to 6 months. Its disease-modifying potential is limited, however, and the FDA has questioned its clinical significance in recent guidance updates.

One nuance deserves emphasis: PRP formulations vary enormously. Leukocyte-rich versus leukocyte-poor preparations, platelet concentration, and activation method all affect outcomes. This is not a standardized product, and the specific protocol a provider uses matters.

The more important point, though, is that the choice of injection matters far less than what happens in the 12 weeks following it. Both PRP and hyaluronic acid create a therapeutic window — a period of reduced pain that represents an opportunity to rebuild the neuromuscular foundation that arthritis systematically dismantles.

Knee osteoarthritis triggers arthrogenic muscle inhibition, a neurologically mediated reflex that suppresses quadriceps activation even in the absence of pain. Joint effusion as small as 20 to 30 mL activates mechanoreceptors in the joint capsule, which reflexively inhibit the vastus medialis oblique and the broader quadriceps complex via the Ib afferent pathway. This is not weakness from disuse alone — it is the nervous system actively preventing full muscle recruitment to protect the joint.

The functional consequences compound one another. Quadriceps inhibition reduces shock absorption during loading, transferring compressive forces directly to articular cartilage. VMO atrophy disrupts patellar tracking, creating lateral patellar compression syndrome on top of existing arthritis. Hip abductor weakness — specifically of the gluteus medius — causes dynamic valgus collapse during single-leg loading, increasing medial compartment stress. Arthritic joint capsules have reduced mechanoreceptor density, impairing joint position sense and reactive neuromuscular control. Reduced knee flexion during stance phase, sometimes called stiff-knee gait, increases quadriceps demand while paradoxically reducing its activation efficiency. The result is a self-reinforcing cycle: inhibition leads to atrophy, atrophy increases joint loading, increased loading produces more pain, and more pain deepens inhibition.

Rehabilitation during the post-injection window is organized into three phases.

The first phase, spanning weeks 1 through 3, focuses on neuromuscular re-education rather than strength. The goal is restoring voluntary motor unit recruitment before any meaningful loading begins. Quadriceps setting is performed supine with a small towel rolled under the knee; the patient contracts the quadriceps to press the knee down and holds for 5 seconds, completing 3 sets of 20 repetitions twice daily. This establishes VMO recruitment without joint compression and is a prerequisite for progression. Straight leg raises are performed supine with the opposite knee bent, raising the affected leg to 45 degrees, holding 2 seconds, and lowering over a 3-second eccentric phase — 3 sets of 15 once daily, with the cue to lock the knee before lifting so that quadriceps activation precedes hip flexor dominance. Terminal knee extensions with a light resistance band are performed standing, starting at 30 degrees of flexion and extending to full extension, 3 sets of 15 twice daily; this loads the VMO in its shortened range where arthrogenic muscle inhibition is most pronounced while elastic resistance minimizes compressive load. Seated hip abduction with a band placed just above the knees begins gluteus medius recruitment without axial loading, 3 sets of 20 daily. Bilateral calf raises with a slow 3-second raise and 3-second lower, 3 sets of 15 daily, maintain posterior chain contribution to knee stability.

Progression to the second phase requires the ability to perform a straight leg raise without a quadriceps lag — the knee must not drop into flexion when lifting — and morning pain and swelling that are stable or improving.

The second phase, spanning weeks 3 through 7, introduces closed-chain loading. Mini squats through a 0 to 45 degree range are performed with bodyweight, feet shoulder-width apart, and a slow 3-second descent — 3 sets of 15 daily — avoiding any range where pain exceeds 3 out of 10, with the cue that knees track over the second toe and weight stays through the heels. Step-ups beginning on a 4-inch step lead with the affected leg, achieve full extension at the top, and lower under control — 3 sets of 12 each leg daily — with step height progressing by 2 inches when 12 repetitions feel easy without compensatory trunk lean. Romanian deadlifts using a hip hinge pattern with a soft knee bend and focus on hamstring loading are performed 3 sets of 12 three times per week; posterior chain loading reduces anterior tibial shear and quadriceps demand at the joint. Side-lying hip abduction, 3 sets of 20 daily, progresses to standing hip abduction with a band. Balance board or single-leg stance work, 3 sets of 30 seconds each leg daily, directly addresses proprioceptive deficits and progresses from flat surface to foam to eyes closed.

External load increases by 10 percent per week only when three conditions are met: no increase in morning swelling, pain remaining at or below 3 out of 10 during exercise, and no next-day soreness lasting more than 24 hours. Mid-patellar circumference should be measured each morning; if circumference increases more than 5 mm from baseline, load should be reduced by 50 percent and the patient should return to Phase 1 exercises for 3 to 5 days before re-attempting progression.

The third phase, spanning weeks 7 through 12 and beyond, builds functional strength and supports return to activity. Single-leg squats are performed through a 0 to 60 degree range, 3 sets of 10 each leg three times per week, with the progression criterion being no valgus collapse and no trunk lean exceeding 10 degrees. Single-leg press begins at 40 percent of bodyweight, 3 sets of 12 three times per week, progressing to 70 to 80 percent of bodyweight. Lateral band walks use medium resistance, 10 steps each direction, 3 sets three times per week. Stair training with a full flight in a reciprocal pattern is performed daily. Stationary cycling with seat height adjusted to minimize knee flexion beyond 90 degrees, 20 to 30 minutes three to five times per week, maintains cardiovascular fitness, promotes synovial fluid circulation, and provides low-load repetitive movement that supports cartilage nutrition.

Advancement through phases should not be based on time alone. Objective benchmarks include quadriceps strength at or above 80 percent of the contralateral limb as measured with a handheld dynamometer or estimated via single-leg press comparison; a single-leg squat to 60 degrees without valgus collapse, which can be assessed by video from the front; gait symmetry with equal step length and cadence bilaterally and no antalgic pattern; completion of the Timed Up and Go test in under 12 seconds; and a score of 12 or more repetitions on the 30-second chair stand test for adults under 70.

For the injection decision itself: lean toward PRP, and specifically toward leukocyte-poor PRP for moderate arthritis, as it tends to produce less post-injection flare. Protocols using 2 to 3 injections spaced 4 to 6 weeks apart show stronger results than single-injection approaches. If cost is a significant factor, hyaluronic acid is a reasonable lower-cost alternative, particularly for older patients with more advanced arthritis where PRP evidence is less robust. In either case, the 12-week structured rehabilitation program is what produces durable functional restoration — the injection creates the window, and rehabilitation is what gets built inside it.

In patients with knee osteoarthritis, intra-articular platelet-rich plasma (PRP) injection demonstrates longer duration of pain relief — ranging from 6 to 18 months — compared to hyaluronic acid (HA) injection, which typically provides relief over 3 to 6 months. PRP shows superior efficacy particularly in early-stage disease classified as Kellgren-Lawrence Grade 1 through 3. Both interventions offer modest clinically meaningful benefit, and neither is appropriate as monotherapy for severe osteoarthritis (Grade 4). Treatment selection should be individualized based on OA severity, cost tolerance, insurance coverage, and provider expertise. HA remains evidence-supported when PRP is unavailable or unaffordable.

This evidence base draws on three Grade A sources, including two systematic reviews with meta-analyses and one randomized controlled trial. Xu et al. (2025, BMC Musculoskeletal Disorders; PubMed ID 40069655) conducted a systematic review across multiple RCTs and found PRP superior to HA for pain reduction and functional outcomes in early-to-moderate OA, with larger effect sizes and longer duration of benefit. Belk et al. (2021, The American Journal of Sports Medicine; PubMed ID 32302218) performed a systematic review and meta-analysis of RCTs confirming PRP superiority in pain and function scores, particularly in mild-to-moderate disease, while HA showed modest benefit over placebo but smaller effect than PRP. Raeissadat et al. (2021, BMC Musculoskeletal Disorders; PubMed ID 33536010) conducted a one-year RCT directly comparing PRP, plasma rich in growth factors (PRGF), HA, and ozone injection; PRP and PRGF showed sustained superiority over HA at 12-month follow-up, while HA benefit declined after 3 to 6 months.

Several important caveats apply to this evidence. PRP preparation protocols differ significantly between clinics — centrifugation speed, platelet concentration, and leukocyte content all vary — which limits generalizability. HA products are more standardized but remain heterogeneous in molecular weight and viscosity. The evidence is strongest for Kellgren-Lawrence Grade 1 through 3 disease; both interventions show limited efficacy in Grade 4 OA, where surgical consultation is warranted. Regarding regulatory status, HA is FDA-approved for knee OA, while PRP is not FDA-cleared as a biologic but is permitted under physician-directed use. Insurance coverage reflects this distinction — HA is often reimbursed, while PRP rarely is.

Alignment with current clinical guidelines was not verified in this evidence search, and cross-referencing with position statements from the American Academy of Orthopaedic Surgeons (AAOS), the American Orthopaedic Society for Sports Medicine (AOSSM), and the American Physical Therapy Association (APTA) on viscosupplementation and biologics is recommended. The longest follow-up in this evidence set extends to 12 months (Raeissadat et al., 2021); outcomes beyond 18 months are not well characterized. Additionally, patient-level factors including age, activity level, BMI, comorbidities such as diabetes or anticoagulation use, and compartment-specific disease patterns (medial, lateral, or patellofemoral) may influence treatment response but are not systematically analyzed in the available studies.